Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more
Zymeworks Inc. Common Stock (ZYME) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.098x
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has a cash flow conversion efficiency ratio of -0.098x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.41 Million) by net assets ($320.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zymeworks Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zymeworks Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zymeworks Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hisense Kelon Electrical Holdings Co Ltd
SHE:000921
|
0.104x |
|
iQIYI Inc
NASDAQ:IQ
|
-0.020x |
|
KCC Corporation
KO:002380
|
0.018x |
|
Integral Ad Science Holding LLC
NASDAQ:IAS
|
0.044x |
|
Ipsos SA
OTCGREY:IPSOF
|
0.077x |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
-0.611x |
|
Sinomach Precision Industry Co Ltd
SHE:002046
|
-0.034x |
|
CCC S.A.
WAR:CCC
|
0.290x |
Annual Cash Flow Conversion Efficiency for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Zymeworks Inc. Common Stock from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $338.77 Million | $-110.04 Million | -0.325x | -27.63% |
| 2023-12-31 | $464.81 Million | $-118.30 Million | -0.255x | -187.06% |
| 2022-12-31 | $492.96 Million | $144.11 Million | 0.292x | +137.84% |
| 2021-12-31 | $249.09 Million | $-192.45 Million | -0.773x | -109.18% |
| 2020-12-31 | $409.92 Million | $-151.40 Million | -0.369x | -10.86% |
| 2019-12-31 | $245.68 Million | $-81.85 Million | -0.333x | -348.72% |
| 2018-12-31 | $180.49 Million | $24.18 Million | 0.134x | +7021.35% |
| 2017-12-31 | $116.43 Million | $219.00K | 0.002x | +100.05% |
| 2016-12-31 | $9.00 Million | $-35.25 Million | -3.915x | -222.11% |
| 2015-12-31 | $18.24 Million | $-22.17 Million | -1.216x | -589.12% |
| 2014-12-31 | $39.78 Million | $-7.02 Million | -0.176x | -- |